Biosimilars Tip NICE Decision on Bowel Cancer Drug

by | Dec 24, 2025 | Health

Spread the love
NICE has approved bevacizumab with chemotherapy for untreated metastatic colorectal cancer, citing improved survival and better value from biosimilars.
Medscape News UK

Written By

Written by Albert Pham, News Curator and Blogger

Related Posts

0 Comments